ALEC News
High-Stakes Corporate Stories Putting Strategic Moves in the Spotlight
Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.
24-7 Market News
High-Stakes Corporate Stories Putting Strategic Moves in the Spotlight
Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.
24-7 Market News
Alector Raises $75 Million in Premium-Priced Stock Offering as Big Biotech Investors Back Fight Against Brain Disease
Alector (NASDAQ:ALEC) is putting $75 million on the table in a major financing move that could help fuel its next chapter in the race to develop treatments for Alzheimer’s, Parkinson’s and other devastating neurological disorders. The South San Francisco biotech priced an underwritten offering of 36.6 million common shares at $2.05 apiece, approximately 7.3% above its October 15 closing price.
24-7 Market News
Biotech Junior Gains 21% as US$100M Upfront Pharma Deal Extends Cash Runway
Securing upfront cash equal to roughly half of its market value sent a small neuroscience developer sharply higher Monday, a reminder of how much a big pharma license can say about a preclinical delivery platform. Alector Inc. (NASDAQ: ALEC) rallied after signing an exclusive global license agreement with Genentech, a member of the Roche Group, for AL050, its brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. Alector will receive US$100M upfront and is eligible for up to US$1.17B in development, regulatory and commercial milestone payments, plus tiered ...
AllPennyStocks.com
Biotech Junior Gains 21% as US$100M Upfront Pharma Deal Extends Cash Runway
Securing upfront cash equal to roughly half of its market value sent a small neuroscience developer sharply higher Monday, a reminder of how much a big pharma license can say about a preclinical delivery platform. Alector Inc. (NASDAQ: ALEC) rallied after signing an exclusive global license agreement with Genentech, a member of the Roche Group, for AL050, its brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. Alector will receive US$100M upfront and is eligible for up to US$1.17B in development, regulatory and commercial milestone payments, plus tiered ...
AllPennyStocks.com
Brainiacs, Space Men, and Digital Assets
This week’s action puts Alector (NASDAQ:ALEC), NeOnc Technologies (NASDAQ:NTHI), WISeQey (NASDAQ:WKEY), Veea (NASDAQ:VEEA), and Stablecoin Development Corporation (NYSEAMERICAN:SDEV) squarely in that conversation.
24-7 Market News
Alector Lands $1.27 Billion Genentech Deal, as Brain-Delivery Platform Gets a Major Validation
Alector (NASDAQ:ALEC) just transformed one of its most important neuroscience programs into a potentially billion-dollar commercial opportunity.
24-7 Market News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million.
NeuroSense Therapeutics (NASDAQ:NRSN) shares increasedread more...
Benzinga
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.read more...
Benzinga